COM902
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda[1].
Product Specifications
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=[C][M902]
References & Citations
[1]Hansen K, et al. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Dec;70 (12) :3525-3540.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
147313 50 µg
IL33, Control Peptide (Interleukin-33, IL-33, Interleukin-1 Family Member 11, IL-1F11, Nuclear Factor From High Endothelial Venules, NF-HEV, C9orf26, IL1F11, NFHEV)
Sign In for Pricing
View Details IHUCOV2NTMET1ALA419RHISLY100UG 100 µg
Human SARS-CoV-2 (COVID-19) Nucleocapsid Met 1 - Ala 419 Recombinant Protein His Tag Lyophilized 100UG
Sign In for Pricing
View Details 210071-01 20 µL
CDK9 (Cyclin-dependent Kinase 9, TAK, C-2k, CTK1, CDC2L4, PITALRE) discontinued
Sign In for Pricing
View Details 210071-02 100 µL
CDK9 (Cyclin-dependent Kinase 9, TAK, C-2k, CTK1, CDC2L4, PITALRE) discontinued
Sign In for Pricing
View Details